Olema Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Bain Capital Life Sciences Opportunities IV, L.P. has filed an amendment reporting beneficial ownership of 8.15% of Olema Pharmaceuticals, Inc. common stock.
NASDAQ
Janus Henderson Group plc has reported beneficial ownership of 7,108,488 shares, representing 8.2% of the outstanding common stock of Olema Pharmaceuticals, Inc.
NASDAQ
Raymond Debbane and affiliated entities, including Invus Public Equities, report a combined beneficial ownership of 5.1% in Olema Pharmaceuticals, Inc.
NASDAQ
FMR LLC and its affiliates, including Abigail P. Johnson, reported a 12.5% beneficial ownership stake in Olema Pharmaceuticals Inc. common stock.
NASDAQ
Deep Track Capital and its affiliates report 0% beneficial ownership in Olema Pharmaceuticals, Inc., indicating a full divestment of their prior stake.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a 6.3% beneficial ownership stake in Olema Pharmaceuticals Inc. common stock as of December 31, 2025.
NASDAQ
Janus Henderson Group plc has reported a 5.2% beneficial ownership stake in Olema Pharmaceuticals, Inc., holding 3,585,849 shares of common stock.
NASDAQ
Point72 Asset Management, L.P., along with its affiliates, has filed an amended Schedule 13G disclosing a 2.3% passive beneficial ownership stake in Olema Pharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.04% in Olema Pharmaceuticals, Inc., totaling 3,442,833 shares.
NASDAQ
Bain Capital Life Sciences Opportunities IV, L.P. has reported a 9.99% beneficial ownership stake in Olema Pharmaceuticals, Inc., totaling 6,843,954 shares, as detailed in its latest Schedule 13G filing.
NASDAQ
SCHEDULE 13G/A: Paradigm BioCapital Entities Disclose Significant Passive Stake in Olema Pharmaceuticals
Paradigm BioCapital Advisors LP and its affiliates have filed an amended Schedule 13G, reporting a collective beneficial ownership of 9.99% in Olema Pharmaceuticals, Inc. as of December 31, 2024.
NASDAQ
Bain Capital Life Sciences Opportunities IV, L.P. has filed an amended Schedule 13G, revealing a 9.99% beneficial ownership stake in Olema Pharmaceuticals, Inc.